The Federal Trade Commission (FTC) approved a final consent order on 25 August 2026 that requires Ascension Health Alliance to divest seven AmSurg ambulatory surgery centers located in five metropolitan areas across the United States. The order is the latest example of the agency’s effort to keep competition alive in outpatient surgical services, where limited provider choice can translate into higher prices, lower quality of care and slower innovation.
What the order requires
According to the FTC press release dated 25 August 2026, Ascension must sell the seven centers to two separate buyers. Six of the centers will be transferred to a group called SC Affiliates, while the seventh center in Panama City, Florida, will be sold to the Florida Gastroenterology Center. The divestiture covers the following metro areas:
| Metro Area | State | Divestiture Buyer |
|---|---|---|
| Nashville | TN | SC Affiliates |
| Panama City | FL | Florida Gastroenterology Center |
| Tulsa | OK | SC Affiliates |
| Waco | TX | SC Affiliates |
| Wichita | KS | SC Affiliates |
| Source: FTC press release (25 Aug 2026) | ||
The order settles the FTC’s allegation that Ascension’s proposed acquisition of AmSurg would limit competition for outpatient procedures performed by gastroenterologists, ophthalmologists and orthopaedic surgeons in those markets.
Why the FTC intervened
The agency’s complaint warned that reduced competition in the five metros could lead to three specific harms for patients:
- Higher surgery prices – with fewer providers, the FTC expects price pressure to tilt upward.
- Lower quality of care – competition often drives hospitals to improve outcomes and patient experience.
- Less innovation – a concentrated market can dampen the incentive to adopt new techniques or equipment.
These concerns are grounded in the FTC’s long‑standing analysis of health‑care mergers, which looks at the number of independent facilities offering the same service, the geographic spread of those facilities, and the ability of patients to travel to alternative providers. In the case of the five metros, the FTC concluded that Ascension’s ownership of all seven AmSurg centers would have created a de‑facto monopoly for certain outpatient specialties.
Background on Ascension Health Alliance and the AmSurg deal
Ascension Health Alliance is a U.S.-based health‑care system. The packet’s only background source is Wikidata, which confirms the company’s name and country of operation but does not list a chief executive, headquarters, employee count or industry classification. The packet explicitly cautions that these details should be verified against Ascension’s own filings before publication. For the purpose of this story, the FTC press release is the only verified source for the transaction details.
The FTC’s order references a proposed $3.9 billion acquisition of AmSurg LLC by Ascension. While the press release does not break down the purchase price by individual center, the overall figure underscores the scale of the deal and why the agency felt a divestiture was necessary to preserve market balance.
Timeline of the regulatory action
The following timeline, drawn from the FTC’s own filing, shows the key steps leading to the final order:
- 25 August 2026 – FTC approves the final consent order, formally requiring Ascension to divest the seven centers.
The order is final; no further court or agency review is anticipated unless either party seeks to modify the terms.
What the divestiture means for patients and providers
For patients in the five affected metros, the immediate effect will be a change in ownership of the facilities where they receive outpatient surgery. The new owners – SC Affiliates and Florida Gastroenterology Center – are independent operators that will continue to offer gastroenterology, ophthalmology and orthopaedic procedures. Because the FTC’s analysis focused on preserving competition, the expectation is that the facilities will remain open and that pricing will be subject to market forces rather than being set by a single dominant system.
Health‑care providers who already operate in those metros may see a modest increase in competitive pressure. Independent surgeons and smaller surgery‑center operators could benefit from a more level playing field, while larger systems will need to compete on price, quality and innovation to retain referrals.
From a policy perspective, the order reinforces the FTC’s broader strategy of scrutinising health‑care mergers that could concentrate outpatient services. The agency has repeatedly highlighted that outpatient surgery is a fast‑growing segment of health‑care spending, and that competition in this niche can have outsized effects on overall health‑care costs for consumers.
What remains unknown
The FTC press release does not disclose the exact transaction dates for each individual divestiture, nor does it provide details on the financial terms of the sales to SC Affiliates or Florida Gastroenterology Center. Additionally, the packet does not contain the name of Ascension’s chief executive, its headquarters location, employee headcount or any recent financial performance metrics. Those facts will need to be confirmed from Ascension’s own filings or public statements before a more detailed profile can be published.
Finally, the long‑term impact on surgery prices will only become clear after the divestitures are completed and the new owners begin operating independently. The FTC’s warning about higher prices is based on economic modelling; actual outcomes will depend on how aggressively the new owners price their services and how other local providers respond.
Looking ahead
With the consent order now in force, the next steps are largely procedural: the seven centers will be transferred to the designated buyers, and the new owners will file the necessary state‑level certifications to continue offering outpatient surgical services. Observers will be watching the transition closely for any signs of service disruption or price changes.
For patients, the key takeaway is that the FTC’s intervention is intended to keep more options on the table. If the competition‑preserving goal is achieved, patients in Nashville, Panama City, Tulsa, Waco and Wichita should continue to have access to multiple providers for gastroenterology, ophthalmology and orthopaedic surgeries, potentially keeping costs lower and quality higher than they would be under a single‑owner scenario.
As the health‑care landscape continues to consolidate, the FTC’s approach in this case may serve as a template for future deals. Stakeholders – from hospital systems to independent surgeons – will need to stay attuned to the agency’s criteria for competition and be prepared to adjust their acquisition strategies accordingly.